A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Key facts
- Who runs it
- Sanofi Pasteur, a Sanofi Company
- Where
- Birmingham, Boston, Charlottesville, Coral Gables, Decatur, DeLand, Farmington Hills, Fort Myers, Kansas City, Knoxville, Las Vegas, Lexington, Maitland, Methuen, Mobile, Newton, North Charleston, Oak Brook, Palmetto Bay, Tempe, and Wichita, United StatesSee the 21 sitesAlso in 1 other country, 3 sites
- Trial code
- NCT06744205
- U1111-1303-3537
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 1,162 people enrolled
- Started
- 6 Jan 2025
- Ended
- 22 May 2026
- Type of study
- Interventional, 11 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
- TIV mRNA-neuraminidase (NA)
- TIV mRNA-HA Vaccine 2
- Quadrivalent Influenza Standard Dose Vaccine
- Quadrivalent Influenza Vaccine High Dose
- Record updated
- 9 June 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Participant aged 50 years on the day of inclusion
- A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:; Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile; OR
- Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration; A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours prior to administration of study intervention
Who cannot take part
- Previous history of myocarditis, pericarditis, and/or myopericarditis
- Known history of previous episodes of Guillain-Barré syndrome, neuritis (including Bell's palsy), convulsions, encephalitis, transverse myelitis, and vasculitis
- Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
- Participant who had acute infectious symptoms or a positive SARS-CoV-2 RT-PCR or antigen test in the past 10 days prior to the first visit (V01)
- Receipt of any vaccine in the 4 weeks preceding study intervention administration or planned receipt of any vaccine in the 4 weeks following study intervention administration
- Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine
- Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration or planned receipt of any mRNA vaccine in the 2 months after study vaccination
- Participation at the time of study enrollment (or in the 4 weeks preceding study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA vaccine
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination based on Investigator's judgment
- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
- Moderate or severe acute illness / infection (according to investigator's judgement) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
- Self-reported or documented seropositivity for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
- Participants are not eligible for the study if any of the following criteria are met:
- Participants with an electrocardiogram that is consistent with possible myocarditis or pericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results
- Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator's judgment
- Receipt of immune globulins, blood or blood-derived products in the past 3 months
Where in United States
Also in 1 other country, 3 sites
- Accel Research Sites Network - Birmingham- Site Number : 8400008Birmingham, United States
- Boston, MassachusettsHospital not named in the registry
- Charlottesville Medical Research- Site Number : 8400004Charlottesville, United States
- Coral Gables, FloridaHospital not named in the registry
- Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400001Decatur, United States
- Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400003DeLand, United States
- Quest Research Institute- Site Number : 8400010Farmington Hills, United States
- Alliance for Multispeciality Research - Fort Myers- Site Number : 8400013Fort Myers, United States
- Alliance for Multispeciality Research - Kansas City- Site Number : 8400019Kansas City, United States
- Alliance for Multispeciality Research - Knoxville- Site Number : 8400017Knoxville, United States
- AMR Las Vegas - Site Number : 8400016Las Vegas, United States
- Alliance for Multispeciality Research - Lexington- Site Number : 8400018Lexington, United States
- Accel Research Sites - Maitland- Site Number : 8400007Maitland, United States
- ActivMed Practices & Research- Site Number : 8400005Methuen, United States
- Mobile, AlabamaHospital not named in the registry
- Alliance for Multispeciality Research - Newton- Site Number : 8400020Newton, United States
- Coastal Carolina Research Center - North Charleston- Site Number : 8400002North Charleston, United States
- Oak Brook, IllinoisHospital not named in the registry
- Innovation Medical Research Center - Palmetto Bay- Site Number : 8400011Palmetto Bay, United States
- Alliance for Multispeciality Research - Clinical Research Consortium- Site Number : 8400015Tempe, United States
- Alliance for Multispeciality Research - Wichita East- Site Number : 8400014Wichita, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
The 11 groups in the trial
- Group 1 - Hexavalent (Combination 1)Treatment being tested
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 1)
Treatment: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA)
- Group 2 - Hexavalent (Combination 2)Treatment being tested
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 2)
Treatment: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA)
- Group 3 - Hexavalent (Combination 3)Treatment being tested
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 3)
Treatment: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA)
- Group 4 - Hexavalent (Combination 4)Treatment being tested
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 4)
Treatment: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA)
- Group 5 - Hexavalent (Combination 5)Treatment being tested
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 5)
Treatment: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA)
- Group 6 - Hexavalent (Combination 6)Treatment being tested
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 6)
Treatment: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA)
- Group 7 - TIV mRNA-HA Vaccine 1Treatment being tested
Participants will receive a single dose of TIV mRNA-HA Vaccine 1
Treatment: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
- Group 8 - TIV mRNA-NATreatment being tested
Participants will receive a single dose of TIV mRNA-NA
Treatment: TIV mRNA-neuraminidase (NA)
- Group 9 - TIV mRNA-HA Vaccine 2Treatment being tested
Participants will receive single dose of TIV mRNA-HA Vaccine 2
Treatment: TIV mRNA-HA Vaccine 2
- Group 10 - QIV-SDExisting treatment, for comparison
Participants will receive single dose of QIV-SD vaccine (for participants 50 to 64 years of age only)
Treatment: Quadrivalent Influenza Standard Dose Vaccine
- Group 11 - QIV-HDExisting treatment, for comparison
Participants will receive single dose of QIV-HD vaccine
Treatment: Quadrivalent Influenza Vaccine High Dose
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older
- Record updated
- 9 June 2026